EMA

The EMA has also announced a plan to expedite study set-up on the back of the Clinical Trials Regulation, coming into force at the end of this month. But beneath the rhetoric of Brexit deregulation, the UK does not want to diverge from international peers

EMA to be given more power and independence in handling COVID-19 pandemic and future health emergencies.  Negotiations between member states and European Parliament are due to begin

Interim accommodation offered by Amsterdam in its winning bid was “not acceptable” says EMA director, Guido Rasi. Now the agency faces a ‘double transfer’ out of London, increasing costs and delaying the return to normal operations

Agency bracing itself for a potential exodus, while pharma companies fear a bottleneck in new drug approvals. Meanwhile, the bill for the removal stands at €400M

City pips Milan in tiebreaker to scoop hotly sought-after prize from London

More than a year after the public consultation closed, EMA and the Commission have announced moves that aim to clear the regulatory logjam holding back commercialisation of therapies based on tissues, cells and genes

Employees are lukewarm on new locations and a slow-down in work rate will mean less income. In the best case scenario Europe’s drugs regulator will take 2-3 years to get back to speed after leaving London.

Only 5 of 19 cities bidding to host the European Medicines Agency would attract enough current employees for operations to continue as normal. Moving to one of the 8 least popular cities risks permanent damage, the agency warns